Perhaps the most significant clinical challenge today is deciding which type of treatment will work best for different prostate cancer patient groups. In the study “Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse” led by Dr. Alfonso Urbanucci from Oslo University Hospital and Professor Matti Nykter from Tampere University, the researchers found that specific patterns in gene expression and DNA organization can predict patient response to treatment.